This was important to determine, because it has been reported that using an inhibitor for CD11b decreases transmigration of CD11b+-cells across endothelial cells and, hence, diminishes the number of infiltrating CD11b+-cells in tumors, resulting in smaller cancers [57,58]. This evidence concerns the gene ITGAM and cancer.